Leukemia & Lymphoma Society Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Leukemia & Lymphoma Society Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0493
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
The Leukemia & Lymphoma Society Inc (LLS) is a voluntary health organization that focuses on funding research for identifying cure for blood cancer. The organization also assures access to treatments for blood cancer patients. Its offers patient support, health education, policy advocacy, and raises funds and funds for medical research. LLS’ provides treatment for various diseases, including leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms and myeloma. The organization works in collaboration with pharmaceutical and biotechnology companies, patients support services and advocates working for blood cancer patients. It has operations in the US and Canada. LLS is headquartered in Rye Brook, New York, the US.

Leukemia & Lymphoma Society Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
OncoPep Raises USD7 Million in Series B Venture Financing 10
Partnerships 11
NexImmune and Leukemia & Lymphoma Society Enter into Partnership 11
Selvita Enters into Agreement with Leukemia & Lymphoma Society 12
Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 13
Evotec Enters Into Research Agreement With Leukemia & Lymphoma Society 14
Stemline Therapeutics Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 15
Constellation Pharma Enters Into Agreement With Leukemia & Lymphoma Society To Develop BET Inhibitors Drugs For Hematologic Cancers 16
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 17
Equity Offering 18
Kiadis Pharma Raises USD0.8 Million in Second Tranche of Private Placement of Shares 18
Kiadis Pharma Raises USD1 Million in Private Placement of Shares 19
Leukemia & Lymphoma Society Inc – Key Employees 20
Leukemia & Lymphoma Society Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Corporate Communications 23
Mar 16, 2017: LLS APPOINTS DR. GWEN NICHOLS, CHIEF MEDICAL OFFICER 23
Government and Public Interest 24
May 02, 2018: More Progress on LLS-Supported CAR T-cell Immunotherapy, A Revolutionary Approach to Cancer Treatment 24
Dec 06, 2017: Study Uses Genetic Testing to Personalize Treatment for Deadly Blood Cancer 25
Nov 21, 2017: The Leukemia & Lymphoma Society awards grant to Savoldo for immunotherapy research 26
Jan 16, 2017: Cancer genetics refine treatment decisions 27
Product News 29
Dec 06, 2017: The Leukemia & Lymphoma Society Achieves New Milestones in Offensive Against Acute Myeloid Leukemia, Deadly Blood Cancer 29
Dec 06, 2017: The Leukemia Lymphoma Society Achieves New Milestones in Offensive Against Acute Myeloid Leukemia, Deadly Blood Cancer 31
Mar 15, 2018: Huntsman Cancer Institute Joins National Clinical Trial Targeting AML 33
Other Significant Developments 34
Nov 20, 2017: LLS Funds $46 Million in New Research to Find Cures 34
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Leukemia & Lymphoma Society Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
OncoPep Raises USD7 Million in Series B Venture Financing 10
NexImmune and Leukemia & Lymphoma Society Enter into Partnership 11
Selvita Enters into Agreement with Leukemia & Lymphoma Society 12
Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 13
Evotec Enters Into Research Agreement With Leukemia & Lymphoma Society 14
Stemline Therapeutics Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 15
Constellation Pharma Enters Into Agreement With Leukemia & Lymphoma Society To Develop BET Inhibitors Drugs For Hematologic Cancers 16
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 17
Kiadis Pharma Raises USD0.8 Million in Second Tranche of Private Placement of Shares 18
Kiadis Pharma Raises USD1 Million in Private Placement of Shares 19
Leukemia & Lymphoma Society Inc, Key Employees 20
Leukemia & Lymphoma Society Inc, Subsidiaries 22

List of Figures
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Leukemia & Lymphoma Society Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Applied Industrial Technologies, Inc.:企業の戦略・SWOT・財務情報
    Applied Industrial Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Applied Industrial Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Pepticom Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Pepticom Ltd (Pepticom) is a drug discovery and development company focused on novel peptide drug candidates. The company's artificial intelligence platform for peptide design models based on the target's solved crystal structure of the target protein. Its products includes copaxone, used fo …
  • Araca Energy ASA:石油・ガス:M&Aディール及び事業提携情報
    Summary Araca Energy ASA (Araca Energy), formerly Aladdin Oil & Gas Company ASA is an oil and gas company that explores, acquires, extracts, develops, and produces oil and gas assets in Russia and other countries. The company conducts its oil and gas exploration, production and operations through it …
  • DesignMedix Inc-製薬・医療分野:企業M&A・提携分析
    Summary DesignMedix Inc (DesignMedix) is a biotechnology company that develop drugs to overcome drug resistance in multiple diseases including malaria and diarrhea. The company focuses on the development of malaria cure drugs, malaria preventive drugs and anti-bacterial drugs. Its malaria cure drugs …
  • Wellcome Trust Sanger Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary Wellcome Trust Sanger Institute (Sanger Institute) a subsidiary of Genome Research Ltd is a genomic discovery and research centre that carries out research and development in the areas of cellular and human genetics and infection genomics. It also provides postgraduate training on research a …
  • Mindray Medical International Limited:企業の戦略・SWOT・財務情報
    Mindray Medical International Limited - Strategy, SWOT and Corporate Finance Report Summary Mindray Medical International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • EnviroMission Limited:企業の戦略的SWOT分析
    EnviroMission Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Cobham plc:企業の戦略・SWOT・財務情報
    Cobham plc - Strategy, SWOT and Corporate Finance Report Summary Cobham plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Erytech Pharma SA (ERYP):企業の財務・戦略的SWOT分析
    Summary Erytech Pharma SA (Erytech) is a clinical-stage biopharmaceutical company that provides development of therapies for rare forms of cancer and orphan diseases. The company develops pipeline of product candidates through its proprietary ERYCAPS platform. It offers product candidates which are …
  • Spar Nord Bank A/S:企業の戦略・SWOT・財務情報
    Spar Nord Bank A/S - Strategy, SWOT and Corporate Finance Report Summary Spar Nord Bank A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Correvio Pharma Corp (COM):製薬・医療:M&Aディール及び事業提携情報
    Summary Correvio Pharma Corp(Correvio) formerly known as Cardiome Pharma Corp, is a specialty pharmaceutical company, which develops and commercializes therapies for the treatment and prevention of cardiovascular diseases. The company’s product portfolio includes two marketed products: Brinavess, fo …
  • China Shineway Pharmaceutical Group Ltd (2877):企業の財務・戦略的SWOT分析
    Summary China Shineway Pharmaceutical Group Ltd (China Shineway) is a pharmaceutical company that offers development, manufacture and sales of Chinese medicines. The company’s products comprise shenmai injection, qingkailing injection, huangqi injection, shuxiening injection, wufu xinnaoqing soft ca …
  • The Centre of Excellence for Prevention of Organ Failure:医療機器:M&Aディール及び事業提携情報
    Summary The Centre of Excellence for Prevention of Organ Failure (PROOF Centre) is a healthcare center that provides blood-based biomarker tests. The center conducts biomarker programs to develop simple blood tests for transplant patients and patients with chronic organ disease and biomarkers in tra …
  • Human Stem Cells Institute (ISKJ):企業の財務・戦略的SWOT分析
    Summary Human Stem Cells Institute (HSCI) is a biotech company that provides discovery, research and development, and marketing of proprietary products and services in the areas of regenerative medicine, medical genetics, bio-insurance, gene therapy and biopharmaceutics. The company offers neovascul …
  • Central Reinsurance Corporation:企業の戦略・SWOT・財務情報
    Central Reinsurance Corporation - Strategy, SWOT and Corporate Finance Report Summary Central Reinsurance Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Allergan plc:企業のM&A・事業提携・投資動向
    Allergan plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Allergan plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Matisa Materiel Industriel S.A.:企業の戦略・SWOT・財務分析
    Matisa Materiel Industriel S.A. - Strategy, SWOT and Corporate Finance Report Summary Matisa Materiel Industriel S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • UCL Business PLC-医療機器分野:企業M&A・提携分析
    Summary UCL Business PLC (UCLB), a subsidiary of University College London is a technology transfer company that supports and markets research and innovations. The company offers licensing technologies and innovations, creates shared risk joint venture businesses, and promotes and supports the trans …
  • Isagen SA ESP:発電所・企業SWOT分析
    Isagen SA ESP - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • PT Perusahaan Gas Negara (Persero) Tbk (PGAS):企業の財務・戦略的SWOT分析
    PT Perusahaan Gas Negara (Persero) Tbk (PGAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆